

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

IN RE PHARMACEUTICAL INDUSTRY
AVERAGE WHOLESALE PRICE
LITIGATION

THIS DOCUMENT RELATES TO:

TRACK 2 SETTLEMENT

MDL No. 1456
Civil Action No. 01-CV-12257-PBS

Hon. Patti B. Saris

CORRECTED EXHIBIT A “T2-SETTLEMENT – EXHIBIT B DRUGS CHART”

On August 3, 2011 Defendants filed their Memorandum in Support of the T2 Class Action Settlement attaching to it as part of Group Exhibit A a T2-Settlement Exhibit B Drugs Chart ("Drug Chart"). Attached hereto is a corrected copy of the Drug Chart adjusted to resolve a formatting error in the final column and to reflect that counsel was able to confirm that promethazine was the subject of discovery in this litigation.

Dated: August 5, 2011

By: /s/ Tina M. Tabacchi

Tina M. Tabacchi
Carol P. Geisler
JONES DAY
77 W. Wacker Drive
Chicago, IL 60601
Telephone: (312) 782-3939
Facsimile: (312) 782-8585

Counsel for Defendant
ABBOTT LABORATORIES INC.

CERTIFICATE OF SERVICE

I hereby certify that a copy of the foregoing Corrected Exhibit B “T2 Settlement – Exhibit B Drugs” Chart was served, this 5th day of August, 2011, on all counsel of record via Lexis Nexis File and Serve pursuant to paragraph 11 of Case Management Order No. 2.

/s/ Carol P. Geisler

Carol P. Geisler

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Anzemet	A	Brand	An anti-emetic used in chemotherapy and post surgery	Aventis	MCCA ¶67; 1st AMCC ¶250 and Appendix A; 2nd AMCC, ¶250; 3rd AMCC ¶266; 4th AMCC ¶263; 5th AMCC ¶263	No	Yes	
Aranesp	A	Brand	Used to treat anemia caused by chronic kidney disease or chemotherapy	Amgen	AMCC ¶ 217; 2nd AMCC ¶217; 3rd AMCC ¶ 233; 4th AMCC ¶ 230; 5th AMCC ¶ 230	No	Yes	
Epogen	A	Brand	Used to treat anemia caused by chronic kidney disease in patients on dialysis	Amgen	CAC ¶ 24, MCCA ¶¶ 56, 192-94; 2nd AMCC ¶217; 3rd AMCC ¶ 233; 4th AMCC ¶ 230; 5th AMCC ¶ 230	No	Yes	
Ferrlecit	A	Brand	Used by patients with renal disease for treatment of iron deficiency	Watson	AMCC ¶ 526; 2nd AMCC ¶ 526, Appendix A; 3rd AMCC ¶¶ 537, 542, Appendix A; 4th AMCC ¶ 487, Appendix A, 5th AMCC ¶ 488	No	Yes	
InFed (iron dextran)	A	Brand	Used by patients with renal disease for treatment of iron deficiency	Watson	MCCAC ¶¶ 130, 327; AMCC ¶¶ 130, 526, 534; 2nd AMCC ¶¶ 130, 526, 534, Appendixes A and B; 3rd AMCC ¶¶ 147, 537, 545, Appendix B; 4th AMCC ¶¶ 40, 144, 487, 595 Appendix A, 5th AMCC ¶ 488	No	Yes	
Neulasta	A	Brand	Used to reduce the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils (a type of blood cell needed to fight infection).used to reduce the risk of infection (initially marked by fever) in chemotherapy patients	Amgen	AMCC ¶ 217; 2nd AMCC ¶217; 3rd AMCC ¶ 233; 4th AMCC ¶ 230; 5th AMCC ¶ 230	No	Yes	
Neupogen	A	Brand	Used to decrease the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils (a type of blood cell needed to fight infection), in people who are undergoing bone marrow transplants, and in people who have severe chronic neutropenia (condition in which there are a low number of neutrophils in the blood)	Amgen	CAC ¶ 24, MCCA ¶¶ 56, 192-94; 2nd AMCC ¶217; 3rd AMCC ¶ 233; 4th AMCC ¶ 230; 5th AMCC ¶ 230	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Group B is comprised primarily of generic and multi-source drugs. Many of the products are hospital products administered in the hospital inpatient (Medicare Part A) and hospital outpatient (Medicare Part B OPPTS - not based on AWP) setting. Group B also includes certain biologics. Since biologics are produced from human material, they are not subject to the provisions of the Hatch-Waxman Act allowing for generic entry through the approval of an abbreviated new drug application. Nonetheless, the biologics identified below all have multiple competitors and the competing biologics are reimbursed using the same J code and are akin, for reimbursement purposes, to innovator multiple source drugs.								
AccuNeb	B	Brand	Indicated for the relief of bronchospasm	Dey	AMCC ¶ 83, 2nd AMCC ¶ 83, 3rd AMCC ¶ 106, 4th AMCC ¶ 107; Revised 5th AMCC ¶ 107	No	Yes	
Acetylcysteine	B	Generic	Primarily used in the hospital setting to thin mucus in lungs	Abbott	MCCAC ¶¶ 54, 190; AMCC ¶¶ 40, 201, 208; 2nd AMCC ¶¶ 40, 201, 208, Appendix A, Amended List of Purchases Made by Plaintiffs; 3rd AMCC ¶¶ 63, 217, 224, Appendix A, Amended List of Purchases Made by Plaintiffs; 4th AMCC ¶¶ 71, 214, 221	No	Yes	
				Dey	MCCAC ¶¶ 90, 251, AMCC ¶¶ 81, 349, 359, 360, Appendix A; 2nd AMCC ¶¶ 81, 349, 359, 360, Appendix A; 3rd AMCC ¶¶ 104, 365, 375, 376, Appendix A. 4th AMCC, ¶¶ 105, 337, 347, 348, Appendix A ; Revised 5th AMCC ¶ 105, 337, 347, 348	No	Yes	
Acyclovir Sodium	B	Generic	Primarily used in the hospital setting as an antiviral	Abbott	MCCAC ¶¶ 54, 190; AMCC ¶¶ 40, 201; 2nd AMCC ¶¶ 40, 201, 208, Appendix A, Appendix B; 3rd AMCC ¶¶ 63, 217, 224, Appendix A, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 71, 214, 221	No	Yes	
				Fujisawa	MCCAC ¶93; AMCC ¶¶86, 364, 371, Appendix A; 2nd AMCC ¶ ¶86, 364, 371, Appendix A; 3rd AMCC ¶ ¶109, 380, 387, Appendix A; 4th AMCC ¶ ¶110, 381, 388, Appendix A; 5th AMCC ¶ ¶110, 353, 360-63	No	Yes	
				Sicor	MCCAC ¶ 323; AMCC ¶¶ 492, 501; 2d AMCC ¶¶ 492, 501; 3d AMCC ¶¶ 503, 512, Appendix A; 4th AMCC ¶¶ 472, 481, Appendix A; 5th AMCC ¶¶ 473, 482	No	Yes	
Adenosine	B	Generic	Primarily used in the hospital setting to treat arrhythmia	Abbott	4th AMCC ¶ 16	Yes	Yes	
				Fujisawa	4th AMCC, Appendix A; 5th AMCC	Yes	Yes	
Adriamycin PFS/RFS	B	Multi-Source	Oncolitic	Pharmacia	1st AC ¶¶ 181, 183, 184, 185, 186; 2nd AMCC ¶¶ 115, 458, 463, 464, 465, 466, 471, 472, Ex. A, Ex. B; 3rd AMCC ¶¶ 132, 469, 474, 475, 476, 477, 481, 482, 483, Ex. A, Ex. B; 4th AMCC ¶¶ 133, 438, 443, 444, 445, 451, 452, 454, App. A, App. B; 5th AMCC ¶¶ 133, 439, 444, 445, 446, 447, 452, 453, 455	No	Yes	
Adrucil [see Fluorouracil]	B	Multi-Source	Oncolitic	Pharmacia	CAC ¶ 41; 2nd AMCC ¶¶ 115, 458, 466, 472, Ex. A, Ex. B; 3rd AMCC ¶¶ 40, 132, 469, 477, 483, Ex. A, Ex. B; 4th AMCC ¶¶ 133, 438, 446, 452, App. A, App. B; 5th AMCC ¶¶ 133, 439, 447, 452	No	Yes	
Aggrastat	B	Multi-source	Primarily used in inpatient surgery in connection with angioplasty	Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A; 3rd AMCC ¶ 288, App A; 4th AMCC ¶ 285; 4th AMCC Revised App A; 5th AMCC ¶ 285	No	Yes	
Albuterol sulfate	B	Generic	Respiratory inhalation drug that is primarily used for relief of bronchospasm in patients with reversible obstructive airway disease and acute attacks of bronchospasm	Dey	MCCAC ¶¶ 90, 246-249; 251-253; AMCC ¶¶ 81, 349, 351, 352, 353, 356, 357, 358, 359, 360. Appendix A; 2nd AMCC, ¶¶ 81, 349, 351, 352, 353, 356, 357, 358, 359, 360, Appendix A; 3rd AMCC, ¶¶ 104, 365, 367, 368, 369, 372, 373, 374, 375, 376, Appendix A; 4th AMCC ¶¶ 105, 337, 339, 340, 341, 344, 345, 346, 347, 348, Appendix A; Revised 5th AMCC ¶ 105, 337, 339, 340, 341, 344, 345, 346, 347, 348	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Alcohol injection	B	Generic	Primarily used in the hospital setting to treat chronic spinal and neck pain	Abbott	3rd AMCC ¶ 230, 4th AMCC ¶ 227	No	Yes	
A-methapred	B	Generic (proprietary name)	Primarily used in the hospital setting as a steroid used to treat inflammation	Abbott	CAC ¶ 19; AMCC ¶ 201; 2nd AMCC ¶¶ 201, Appendix A, Amended List of Purchases Made by Plaintiffs; 3rd AMCC ¶¶ 217, Appendix A, Amended List of Purchases Made by Plaintiffs; 4th AMCC ¶ 214	No	Yes	
Amikacin sulfate	B	Generic	Primarily used in the hospital setting as an antibiotic	Abbott	MCCAC ¶¶ 54, 188, 190; AMCC @ TOC, ¶¶ 40, 201, 208; 2nd AMCC @ TOC, ¶¶ 40, 201, 208, 212, Appendix A, Appendix B; 3rd AMCC @ TOC, ¶¶ 63, 217, 224, 228, Appendix A, Amended List of Purchases Made By Plaintiffs; 4th AMCC @ TOC, ¶¶ 71, 214, 221, 225	No	Yes	
				Sicor	MCCAC ¶ 323; AMCC ¶¶ 124, 492, 501; 2d AMCC ¶¶ 124, 492, 501; 3d AMCC ¶¶ 141, 503, 512, Appendix A; 4th AMCC ¶¶ 142, 472, 481, Appendix A; 5th AMCC ¶¶ 142, 473, 482	No	Yes	
Aminocaproic acid	B	Generic	Primarily used in the hospital setting to stop bleeding	Abbott	3rd AMCC ¶ 230, 4th AMCC ¶ 227	No	Yes	
Aminosyn / Aminosyn II / Amino acid	B	Multi-Source	Primarily used in the hospital setting to treat nitrogen loss or negative nitrogen balance	Abbott	AMCC ¶ 201; 2nd AMCC ¶ 201, Appendix A, Appendix B; 3rd AMCC ¶¶ 217, 230, Appendix A, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 214, 227	No	Yes	
Amphocin / Amphotericin B	B	Generic	Primarily used in the hospital setting as an antifungal	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
				Pharmacia	2nd AMCC ¶¶ 115, 458, 466, 472, Ex. A, Ex. B; 3rd AMCC ¶¶ 132, 469, 477, 483, Ex. A, Ex. B; 4th AMCC ¶¶ 133, 438, 446, 452, App. A, App. B; 5th AMCC ¶¶ 133, 439, 447, 453	No	Yes	
				Sicor	AMCC ¶ 492; 2d AMCC ¶ 492; 3d AMCC ¶ 503, Appendix A; 4th AMCC ¶ 472, Appendix A; 5th AMCC ¶ 473	No	Yes	
Aristocort	B	Branded Multi-Source	Oral cortiosteroid used primarily in hospital setting to treat inflammation	Fujisawa	AMCC ¶ 364, Appendix A; 2nd AMCC ¶371, Appendix A; 3rd AMCC ¶380, Appendix A; 4th AMCC ¶381, Appendix A; 5th AMCC ¶353	No	Yes	
Aristospan	B	Branded Multi-Source	Injectable cortiosteroid used primarily in hospital setting to treat inflammation	Fujisawa	AMCC ¶ 364, Appendix A; 2nd AMCC ¶371, Appendix A; 3rd AMCC ¶380, Appendix A; 4th AMCC ¶381, Appendix A; 5th AMCC ¶353	No	Yes	
Aromasin	B	Brand	Oncolitic	Pharmacia	2nd AMCC ¶ 115; 3rd AMCC ¶ 132; 4th AMCC ¶ 133; 5th AMCC ¶ 133	No	Yes	
Ativan	B	Multi-source	Primarily used in the hospital setting to treat anxiety disorders	Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A, App B; 3rd AMCC ¶ 288, App A, App B; 4th AMCC ¶ 285; 4th AMCC Revised App A, App B; 5th AMCC ¶ 285	No	Yes	
Azmacort	B	Brand	A corticosteroid used primarily to treat symptoms of asthma (wheezing, shortness of breath) and other lung diseases	Aventis	1st AMCC ¶250, and Appendix A; 2nd AMCC ¶250; 3rd AMCC ¶266; 4th AMCC ¶263; 5th AMCC ¶263	No	Yes	
Bebulin	B	Multi-Source Biologic	Anti-hemophilic factor used to treat hemophilia	Baxter	MCCAC ¶ 71; AMCC ¶¶ 60, 272; 2nd AMCC ¶¶ 60, 272, App A; 3rd AMCC ¶¶ 83, 288, App A; 4th AMCC ¶¶ 91, 285; 4th AMCC Revised App A; 5th AMCC ¶¶ 91, 285	No	Yes	
Bioclalte	B	Multi-Source Biologic	Anti-hemophilic factor (recombinant), used to treat hemophilia	Aventis	MCCA ¶67; 1st AMCC ¶55; 2nd AMCC ¶55; 3rd AMCC ¶78; 4th AMCC ¶86; 5th AMCC ¶86	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Bleomycin sulfate	B	Generic	Primarily used in the hospital setting as an antibiotic used in treatment of Hodgkin's lymphoma	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
				Pharmacia	1st Amd Compl. ¶ 183, 187; 2nd AMCC ¶¶ 115, 458, 463, 466, 470, 471, Ex. A, Ex. B; 3rd AMCC ¶¶ 52, 132, 469, 474, 477, 481, 482, Ex. A, Ex. B; 4th AMCC ¶¶ 60, 133, 438, 443, 446, App. A, App. B; 5th AMCC ¶¶ 60, 133, 439, 444, 447	No	Yes	
Brevibloc	B	Multi-source	Primarily used in the hospital setting to slow heart rate during surgery	Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A; 3rd AMCC ¶ 288, App A; 4th AMCC ¶ 285; 4th AMCC Revised App A; 5th AMCC ¶ 285	No	Yes	
Buminate	B	Multi-Source Biologic	Blood product used in the hospital setting for cardiopulmonary surgery	Baxter	MCCAC ¶ 71; AMCC ¶¶ 60, 272; 2nd AMCC ¶¶ 60, 272, App A; 3rd AMCC ¶¶ 83, 288, App A; 4th AMCC ¶¶ 91, 285; 4th AMCC Revised App A; 5th AMCC ¶¶ 91, 285	No	Yes	
Bupivacaine	B	Generic	Primarily used in the hospital setting as a local anaesthetic	Abbott	3rd AMCC ¶¶ 15, 230; 4th AMCC ¶¶ 15, 227	Yes	Yes	
Calcijex	B	Brand through 10/01; thereafter multi-source	Primarily used in the hospital setting as a man-made form of vitamin D	Abbott	CAC ¶ 19; MCCAC ¶ 190; AMCC ¶ 201; 2nd AMCC ¶¶ 201, 208, Appendix A, Appendix B; 3rd AMCC ¶¶ 217, 224, Appendix A, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 214, 221	No	Yes	
Calcimar	B	Brand	A human hormone used primarily to treat Paget's disease and osteoporosis in postmenopausal women	Aventis	1st AMCC ¶250, and Appendix A; 2nd AMCC ¶250; 3rd AMCC ¶266; 4th AMCC ¶263; 5th AMCC ¶263	No	Yes	
Camptosar / Irinotecan hydrochloride	B	Brand	Oncolitic	Pharmacia	CAC ¶ 41; 2nd AMCC ¶¶ 115, 467, 468; 3rd AMCC ¶¶ 132, 478, 479; 4th AMCC ¶ 133, 447, 448; 5th AMCC ¶ 133, 448, 449	No	Yes	
Carbocaine / Mepivacaine	B	Generic	Primarily used in the hospital setting as local anaesthetic	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Cefizox	B	Brand	Injectable antibiotic used primarily in hospital setting	Fujisawa	AMCC ¶ 364, Appendix A; 2nd AMCC ¶371, Appendix A; 3rd AMCC ¶380, Appendix A; 4th AMCC ¶381, Appendix A; 5th AMCC ¶353	No	Yes	
Chromium tr meta / Chromic chloride	B	Generic	Primarily used in the hospital setting as an additive to IV solutions for total parenteral nutrition	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Cimetidine hydrochloride	B	Generic	Primarily used in the hospital setting to inhibit production of acid in stomach	Abbott	MCCAC ¶¶ 54, 190; AMCC ¶¶ 40, 201, 208; 2nd AMCC ¶¶ 40, 201, 208, Appendix A, Appendix B; 3rd AMCC ¶¶ 63, 217, 224, Appendix A, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 71, 214, 221	Yes	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Cipro / Ciprofloxacin hydrochloride	B	Generic	Primarily used in the hospital setting as an antibiotic	Abbott	3rd AMCC ¶ 16; 4th AMCC ¶ 17	Yes	Yes	
		Multisource as of June 9, 2004		Bayer	Modified 1st Am. Compl. ¶ 286 (Dec. 8, 2003); 2nd AMCC ¶ 286; 3rd AMCC ¶ 302, Appendix; 4th AMCC ¶¶ 17, 299, Appendix A; Appendix to 4th AMCC	No	Yes	
Cisplatin	B	Multi-source	Primarily used in the hospital setting as a chemotherapy drug	Baxter	MCCAC ¶ 71; AMCC ¶¶ 60, 272; 2nd AMCC ¶¶ 60, 272, App A; 3rd AMCC ¶¶ 83, 288, App A; 4th AMCC ¶¶ 91, 285; 4th AMCC Revised App A; 5th AMCC ¶¶ 91, 285	No	Yes	
				Sicor	4th AMCC ¶¶ 15, 17, 60; 5th AMCC ¶¶ 15, 17, 60	Yes	Yes	
Claforan	B	Multi-source	Primarily used in the inpatient hospital setting to prevent staph infections	Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A; 3rd AMCC ¶ 288, App A; 4th AMCC ¶ 285; 4th AMCC Revised App A; 5th AMCC ¶ 285	No	Yes	
Cleocin T / Clindamycin phosphate	B	Generic	Primarily used in the hospital setting as an antibiotic	Abbott	MCCAC ¶¶ 54, 190; AMCC ¶¶ 40, 201; 2nd AMCC ¶¶ 40, 201, 208, Appendix A, Amended List of Purchases Made By Plaintiffs; 3rd AMCC ¶¶ 63, 224, Appendix A, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 71, 214, 221	No	Yes	
		Branded Multi-Source	Antibiotic	Pharmacia	2nd AMCC ¶¶ 115, 458, 466, Ex. A, Ex. B; 3rd AMCC; ¶¶ 20, 132, 469, 477, Ex. A, Ex. B, 4th ¶¶ 133, 438, 446, 451, App. A, App. B 5th AMCC ¶¶ 133, 439, 447	No	Yes	
Cromolyn sodium	B	Generic	Respiratroy inhalation drug used to treat patients with bronchial asthma	Dey	MCCAC ¶¶ 90, 251. AMCC ¶¶ 81, 349, 355, 359, 360, 362, Appendix A; 2nd AMCC ¶¶ 81, 349, 355, 359, 360, 362, Appendix A, 3rd AMCC, ¶¶ 104, 365, 371, 375, 376, 378, Appendix A; 4th AMCC ¶¶ 105, 337, 343, 347, 348, 350, Appendix A; Revised 5th AMCC ¶¶ 105, 337, 343, 347, 348, 350	No	Yes	
Cytosar-U / Cytarabine	B	Multi-source	Oncolitic	Pharmacia	2nd AMCC ¶¶ 115, 458, 466, Ex. A, Ex. B; 3rd AMCC ¶¶ 132, 469, 477, Ex. A, Ex. B; 4th AMCC ¶¶ 133, 438,446, App. A, App. B; 5th AMCC ¶¶ 133, 439, 447	No	Yes	
Depo provera / Medroxyprogesterone acetate	B	Brand	Contraception	Pharmacia	4th AMCC ¶ 23, Revised App. A; 5th AMCC ¶ 23	Yes	Yes	
Depo-testosterone / Testosterone cypionate	B	Multi-Source	Hormone	Pharmacia	2nd AMCC ¶¶ 115, 458, 466, Ex. A, Ex. B; 3rd AMCC ¶ 132, 469, 477, Ex. A, Ex. B; 4th AMCC ¶¶ 133, 438, 446, App. A, App. B; 5th AMCC ¶¶ 133, 439, 447	No	Yes	
Dexamethasone acetate	B	Generic	Primarily used in the hospital setting as an anti-inflammatory to treat allergic reactions	Abbott	3rd AMCC ¶ 19; 4th AMCC ¶ 21	Yes	Yes	
				Bayer (but not a Bayer drug)	4th AMCC ¶ 21	Yes	Not a Bayer Drug	
				Watson	MCCAC ¶¶ 130, 327; AMCC ¶¶ 130, 526, 534; 2nd AMCC ¶¶ 130, 526, 534, Appendixes A and B; 3rd AMCC ¶¶ 147, 537, 545, Appendix B; 4th AMCC ¶¶ 17, 21, 144, 487, 495, Appendix A, 5th AMCC ¶ 488	No	Yes	
Dexamethasone sodium / Dexamethasone sodium phosphate	B	Generic	Anti-inflammatory, treats allergic reactions, autoimmune disease and certain cancers	Abbott	3rd AMCC ¶ 39; 4th AMCC ¶ 47	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
				Fujisawa	MCCAC ¶¶93; AMCC ¶¶86, 364, 371, Appendix A; 2nd AMCC ¶¶86, 364, 371, Appendix A; 3rd AMCC ¶¶109, 380, 387, Appendix A; 4th AMCC ¶¶110, 381, 388, Appendix A; 5th AMCC ¶¶110, 353, 360-63	No	Yes	
				Sicor	4th AMCC ¶¶15, 17, 18, 21; 5th AMCC ¶¶15, 17, 18, 21	Yes	Yes	
				Watson	MCCAC ¶¶327; AMCC ¶¶526, 534; 2nd AMCC ¶¶526, 534, Appendixes A and B; 3rd AMCC ¶¶537, 545, Appendixes A and B; 4th AMCC ¶¶17, 21, 52, 487, 495, Appendix A, 5th AMCC ¶¶488, 5th AMCC ¶¶488	No	Yes	
Dextrose / Dextrose sodium chloride / Ringers lactated with dextrose	B	Generic	Primarily used in the hospital setting as a diluent	Abbott	MCCAC ¶¶26, 54, 190; AMCC ¶¶29, 40, 201, 208; 2nd AMCC ¶¶29, 40, 201, 208, Appendix A, Appendix B; 3rd AMCC ¶¶15, 16, 21, 63, 217, 224, Appendix A, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶15, 17, 25, 71, 214, 221	No, except for ringers lactated with dextrose inj (but shares J Code with other Dextrose products listed)	Yes	
		Multi-source	Primarily used in the hospital setting as a diluent	Baxter	MCCAC ¶¶71, 217; AMCC ¶¶60, 272; 2nd AMCC ¶¶60, 272, App A; 3rd AMCC ¶¶83, 288, App A; 4th AMCC ¶¶91, 285; 4th AMCC Revised App A; 5th AMCC ¶¶91, 285	No, except for ringers lactated with dextrose inj (but shares J Code with other Dextrose products listed)	Yes	
Diazepam	B	Generic	Primarily used in the hospital setting to treat anxiety and nervousness	Abbott	MCCAC ¶¶54, 190; AMCC ¶¶40, 201 ; 2nd AMCC ¶¶40, 201, 208, Appendix A, Appendix B; 3rd AMCC ¶¶63, 217, 224, Amended List of Purchases Made By Plaintiffs, Purchases Made By Plaintiffs; 4th AMCC ¶¶71, 214, 221	No	Yes	
				Watson	MCCAC ¶¶130, 327; AMCC ¶¶130, 526, 534; 2nd AMCC ¶¶130, 526, 534, Appendixes A and B; 3rd AMCC ¶¶147, 537, 545, Appendixes A and B; 4th AMCC ¶¶144, 487, 495, Appendix A	No	Yes	
Dacarbazine (see DTIC - Dome)	B	Multi-Source	Antineoplastic cancer medication	Bayer	Modified 1st Am. Compl. ¶ 286 (Dec. 8, 2003); 2nd AMCC ¶ 286; 3rd AMCC ¶ 302, Appendix; 4th AMCC ¶ 299, Appendix A; Appendix to 4th AMCC	No	Yes	
Diltiazem hydrochloride	B	Generic	Primarily used in the hospital setting to treat hypertension, angina and some types of arrhythmia	Abbott	3rd AMCC ¶¶15, 20; 4th AMCC ¶ 15	Yes	Yes	
				Sicor	4th AMCC ¶ 15	Yes	Yes	
Dopamine hydrochloride	B	Generic	Primarily used in the hospital setting to improves the heart's contractions	Abbott	3rd AMCC ¶¶19, 230; 4th AMCC ¶¶21, 227; 5th AMCC ¶ 15	Yes	Yes	
Doxorubicin / Doxorubicin hydrochloride [see Adriamycin]	B	Generic	Primarily used in the hospital setting as an oncolitic	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
				Baxter	AMCC ¶¶60, 272; 2nd AMCC ¶¶60, 272, App A; 3rd AMCC ¶¶83, 288, App A; 4th AMCC ¶¶91, 285; 4th AMCC Revised App A; 5th AMCC ¶¶91, 285	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
				Fujisawa	MCCAC ¶¶93; AMCC ¶¶86, 364, 371, Appendix A; 2nd AMCC ¶¶86, 364, 371, Appendix A; 3rd AMCC ¶¶109, 380, 387, Appendix A; 4th AMCC ¶¶110, 381, 388, Appendix A; 5th AMCC ¶¶110, 353, 360-63	No	Yes	
				Pharmacia	See Adriamycin	No	Yes	
				Sicor	AMCC ¶ 492; 2d AMCC ¶¶ 492, 499, 503; 3d AMCC ¶¶ 503, 510, 514, Appendix A; 4th AMCC ¶¶ 472, 479, 483, Appendix A; 5th AMCC ¶¶ 473, 480, 484	No	Yes	
DTIC Dome [see Dacarbazine]	B	Multi-Source	Antineoplastic cancer medication	Bayer	Modified 1st Am. Compl. ¶ 286 (Dec. 8, 2003); 2nd AMCC ¶ 286; 3rd AMCC ¶ 302, Appendix; 4th AMCC ¶ 299, Appendix A; Appendix to 4th AMCC	No	Yes	
Eligard	B	Brand (but shares Jcode with therapeutic equivalent)	Used primarily to treat the symptoms of advanced prostate cancer	Aventis	4th AMCC ¶19; 5th AMCC ¶19	Yes	Yes	
Ellence / Epirubicin HCL	B	Brand	Oncolytic	Pfizer	AMCC ¶ 41; 2nd AMCC ¶ 115; 3rd AMCC ¶¶ 19, 132; 4th AMCC ¶ 133; 5th AMCC ¶ 133	No	Yes	
Enalaprilat	B	Generic	ACE inhibitor	Sicor	4th AMCC ¶ 17; 5th AMCC ¶ 17	Yes	Yes	
Enbrel	B	Brand	Largely self-administered; used to treat moderate to severe rheumatoid arthritis, adult chronic moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and moderate to severe juvenile idiopathic arthritis	Amgen	AMCC ¶ 217; 2nd AMCC ¶217; 3rd AMCC ¶ 233; 4th AMCC ¶ 230; 5th AMCC ¶ 230	No	Yes	
Epinephrine	B	Generic	Primarily used in the hospital setting to treat severe allergic reactions	Abbott	3rd AMCC ¶¶ 15, 230; 4th AMCC ¶¶ 15, 227	Yes	Yes	
				Sicor	4th AMCC ¶ 15; 5th AMCC ¶ 15	Yes	Yes	
Erythromycin / Erythromycin base	B	Generic	Primarily used in the hospital setting as an antibiotic	Abbott	AMCC ¶ 201; 2nd AMCC ¶ 201, Appendix A, Appendix B; 3rd AMCC ¶ 217, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶ 214	No	Yes	
Estradiol	B	Generic	Hormone used for treatment of menopause and postmenopausal osteoporosis	Watson	AMCC ¶ 526; 2nd AMCC ¶ 526, Appendixes A and B; 3rd AMCC ¶ 537, Appendixes A and B; 4th AMCC ¶ 487, 5th AMCC ¶ 488	No	Yes	
Etoposide [see Toposar]	B	Multi-Source		Pharmacia	See Toposar	No	Yes	
		Generic		Sicor	MCCAC ¶ 319; AMCC ¶¶ 492, 496; 2d AMCC ¶¶ 492, 494, 496, 502, 503; 3d AMCC ¶¶ 503, 505, 507, 513, 514, Appendix A; 4th AMCC ¶¶ 17, 60, 472, 474, 476, 482, 483, Appendix A	No	Yes	
Famotidine	B	Generic	Primarily used in the hospital setting as an antihistamine that blocks release of stomach acid	Abbott	3rd AMCC ¶¶ 15, 16; 4th AMCC ¶¶ 15, 17	Yes	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Fentanyl citrate	B	Generic	Primarily used in the hospital setting as a pain reliever	Abbott	AMCC ¶ 201; 2nd AMCC ¶ 201, Appendix A, Appendix B; 3rd AMCC ¶¶ 19, 20, 217, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 15, 17, 21, 214	No	Yes	
Fluorouracil [see Aducril]	B	Multi-source	Oncolitic	Pharmacia	CAC ¶ 41; 2nd AMCC ¶¶ 115, 458, 466, 472, Ex. A, Ex. B; 3rd AMCC ¶¶ 40, 132, 469, 477, 483, Ex. A, Ex. B	No	Yes	
				Fujisawa	MCCAC ¶93; AMCC ¶¶86, 364, 371, Appendix A; 2nd AMCC ¶ ¶86, 364, 371, Appendix A; 3rd AMCC ¶ ¶109, 380, 387, Appendix A; 4th AMCC ¶ ¶110, 381, 388, Appendix A; 5th AMCC ¶ ¶110, 353, 360-63	No	Yes	
Fluphenazine HCL	B	Generic	Psychotherapeutic agent used to manage psychotic disorders	Watson	AMCC ¶¶ 526, 536; 2nd AMCC ¶¶ 526, 536, Appendixes A and B; 3rd AMCC ¶¶ 537, 547, Appendixes A and B; 4th AMCC ¶¶ 487, 495, Appendix A	No	Yes	
Furosemide	B	Generic	Primarily used in the hospital setting as a diuretic	Abbott	MCCAC ¶¶ 26, 54, 190; AMCC ¶¶ 29, 40, 201, 208; 2nd AMCC ¶¶ 29, 40, 201, 208, Appendix A, Appendix B ; 3rd AMCC ¶¶ 15, 20, 21, 32, 42, 63, 217, 224, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 15, 25, 40, 50, 71, 214, 221	No	Yes	
Gamimune N	B	Multi-Source Biologic	Immune globulin used to treat primary immune deficiency	Bayer	MCCAC ¶ 74; AMCC ¶ 63; Modified 1st Am. Compl. ¶¶ 63, 286 (Dec. 8, 2003); 2nd AMCC ¶¶ 63, 286; 3rd AMCC ¶¶ 86, 302, Appendix; 4th AMCC ¶¶ 94, 299, Appendix A; Appendix to 4th AMCC	No	Yes	
Gammagard / Gammagard S/D / Gammar / Gammar P.I.V.*	B	Multi-Source Biologic	A sterilized human plasma solution, used primarily to treat immune deficiency conditions	Baxter	CAC ¶ 28; MCCAC ¶ 71; AMCC ¶¶ 60, 272; 2nd AMCC ¶¶ 60, 272, App A; 3rd AMCC ¶¶ 83, 288, App A; 4th AMCC ¶¶ 91, 285; 4th AMCC Revised App A; 5th AMCC ¶¶ 91, 285	No	Yes	
				Aventis (Gammar PIV)	CAC ¶ 24; MCCAC ¶ 20; AMCC ¶¶ 17, 80; Corrected AMCC dkt 928 ¶¶ 19, 88, App A; 3rd AMCC ¶¶ 29, 97, App A; 4th AMCC ¶¶ 31, 97; 4th AMCC dkt 2244 Revised App A; 5th AMCC dkt 5902 at 31, 97 Aventis (Gammar PIV) - initial cite MCCAC, ¶67, and App. A	No	Yes	
Gentamicin sulfate	B	Generic	Primarily used in the hospital setting to treat infections	Abbott	MCCAC ¶¶ 26, 54, 190; AMCC ¶¶ 29, 40, 201, 208; 2nd AMCC ¶¶ 29, 40, 201, 208, Appendix A, Appendix B; 3rd AMCC ¶¶ 21, 63, 217, 224, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 25, 71, 214, 221	No	Yes	
				Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A; 3rd AMCC ¶ 288, App A; 4th AMCC ¶ 285; 4th AMCC Revised App A; 5th AMCC ¶ 285	No	Yes	
				Fujisawa	MCCAC ¶93; AMCC ¶¶86, 364, 371, Appendix A; 2nd AMCC ¶ ¶86, 364, 371, Appendix A; 3rd AMCC ¶ ¶109, 380, 387, Appendix A; 4th AMCC ¶ ¶110, 381, 388, Appendix A; 5th AMCC ¶ ¶110, 353, 360-63	No	Yes	
				Watson	MCCAC ¶¶ 130, 327; AMCC ¶¶ 130, 526, 534; 2nd AMCC ¶¶ 130, 526, Appendixes A and B; 3rd AMCC ¶¶ 147, 537, Appendixes A and B; 4th AMCC ¶¶ 144, 487, 495, Appendix A	No	Yes	
Gentran / Gentran NACL	B	Multi-source	Primarily used in the hospital/surgical setting as an anti-coagulant	Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A; 3rd AMCC ¶ 288, App A; 4th AMCC ¶ 285; 4th AMCC Revised App A; 5th AMCC ¶ 285	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Glycopyrrolate	B	Generic	Primarily used in the hospital setting to treat peptic ulcer disease	Abbott	3rd AMCC ¶ 15; 4th AMCC ¶ 15; 5th AMCC ¶ 15	Yes	Yes	
				Sicor	4th AMCC ¶ 15	Yes	Yes	
Helixate / Helixate FS	B	Multi-Source Biologic	Anti-hemophilic factor (recombinant), used to treat hemophilia	Aventis	MCCA ¶67; 1st AMCC ¶55; 2nd AMCC ¶55; 3rd AMCC ¶78; 4th AMCC ¶86; 5th AMCC ¶86	No	Yes	
Heparin / Heparin lock flush / Heparin sodium	B	Generic	Primarily used in the hospital setting as an anticoagulant	Abbott	MCCAC ¶¶ 26, 54, 190; AMCC ¶¶ 29, 40, 201, 208; 2nd AMCC ¶¶ 29, 40, 201, 208, Appendix A, Appendix B; 3rd AMCC ¶¶ 15, 19, 20, 21, 63, 217, 224, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 15, 21, 25, 71, 214, 221	No	Yes	
				Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A; 3rd AMCC ¶ 288, App A; 4th AMCC ¶ 285; 4th AMCC Revised App A; 5th AMCC ¶ 285	No	Yes	
Humate-P	B	Multi-Source Biologic	Anti-hemophilic factor/von Willebrand factor complex, used to treat hemophilia and von Willebrand disease	Aventis	MCCA ¶67; 1st AMCC ¶55; 2nd AMCC ¶55; 3rd AMCC ¶78; 4th AMCC ¶86; 5th AMCC ¶86	No	Yes	
Hydromorphone	B	Generic	Primarily used in the hospital setting as a pain reliever	Abbott	3rd AMCC ¶¶ 15, 20; 4th AMCC ¶¶ 15, 17	Yes	Yes	
Idamycin / Idarubicin hydrochloride	B	Brand	Oncolitic	Pharmacia	1st Amd Compl. ¶ 183; 2nd AMCC ¶¶ 115, 463; 3rd AMCC ¶¶ 132, 474; 4th AMCC ¶ 133, 443; 5th AMCC ¶ 133, 144	No	Yes	
Imipramine HCL	B	Generic	Psychotherapeutic agent used in treatment of depression	Watson	AMCC ¶¶ 526, 536; 2nd AMCC ¶¶ 526, 536, Appendix A; 3rd AMCC ¶¶ 537, 547, Appendixes A and B; 4th AMCC ¶¶ 487, 495, 5th AMCC ¶ 488	No	Yes	
Intal	B	Brand	Used primarily to treat symptoms of asthma (wheezing, shortness of breath) and exercise induced bronchospasm	Aventis	1st AMCC ¶250, and Appendix A; 2nd AMCC ¶250; 3rd AMCC ¶266; 4th AMCC ¶263; 5th AMCC ¶263	No	Yes	
Ipratropium bromide	B	Generic	Respiratory inhalation drug used for the maintenance treatment of bronchospasms associated with Chronic Obstructive Pulmonary Disease	Dey	MCCAC ¶¶ 90, 253, AMCC ¶¶ 81, 83, 349, 352, 353, 354, 362, Appendix A; 2nd AMCC, ¶¶ 81, 83, 349, 352, 353, 354, 362, Appendix A; 3rd AMCC, ¶¶, 104, 106, 365, 368, 369, 370, 378, Appendix A, 4th AMCC ¶¶ 105, 107, 337, 340, 341, 342, 350, Appendix A; Revised 5th AMCC, ¶ 105, 107, 337, 340, 341, 342, 350	No	Yes	
Iveegam	B	Multi-Source Biologic	Plasma replacement therapy for immune deficiencies	Baxter	MCCAC ¶ 71; AMCC ¶¶ 60, 272; 2nd AMCC ¶¶ 60, 272, App A; 3rd AMCC ¶¶ 83, 288, App A; 4th AMCC ¶¶ 91, 285; 4th AMCC Revised App A; 5th AMCC ¶¶ 91, 285	No	Yes	
Ketorolac / Ketorolac tromethamine	B	Generic	Primarily used in the hospital setting as an anti-inflammatory to treat pain after surgery	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶¶ 21, 227	Yes	Yes	
			Primarily used in the hospital setting as an anti-inflammatory to treat pain after surgery	Watson	4th AMCC Appendix A	Yes		

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Kineret	B	Brand	Used to reduce signs and symptoms and to slow progression of structural damage in adult patients with moderate to severe rheumatoid arthritis	Amgen	AMCC ¶ 217; 2nd AMCC ¶217; 3rd AMCC ¶ 233; 4th AMCC ¶ 230; 5th AMCC ¶ 230	No	Yes	
Koate- HP	B	Multi-Source Biologic	Antihemophilic factor viii blood product	Bayer	MCCAC ¶ 74; AMCC ¶ 63; Modified 1st Am. Compl. ¶¶ 63, 286; 2nd AMCC ¶¶ 63, 286; 3rd AMCC ¶¶ 86, 302, Appendix; 4th AMCC ¶¶ 94, 299, Appendix A; Appendix to 4th AMCC	No	Yes	
Kogenate	B	Multi-Source Biologic	Antihemophilic factor viii (recombinant)	Bayer	Compl. ¶ 74 (Sept. 6, 2002); 1st Am. Compl. ¶ 63 (July 28, 2003); Modified 1st Am. Compl. ¶¶ 63, 286; 2nd Am. Compl. ¶¶ 63, 286 (Feb. 24, 2005); 3rd Am. Compl. ¶¶ 86, 302, Appendix (Oct. 17, 2005); 4th Am. Compl. ¶¶ 94, 299, Appendix A (March 1, 2006); Appendix to 4th Am. Compl. (March 10, 2006)	No	Yes	
Labetalol	B	Generic	Primarily used in the hospital setting to reduce the workload of the heart	Abbott	3rd AMCC ¶ 16; 4th AMCC ¶ 17	Yes	Yes	
Lasix	B	Brand	A diuretic used to reduce swelling and fluid retention caused by a variety of diseases	Aventis	CAC ¶ 36; 2nd AMCC ¶¶ 567, 570; 3rd AMCC ¶¶ 567, 570	No	Yes	
Leucovorin calcium	B	Generic	Primarily used in the hospital setting as an adjunct to chemotherapy	Abbott	CAC ¶ 36; 2nd AMCC ¶¶ 567, 570; 3rd AMCC ¶¶ 567, 570	No	Yes	
			Chemotherapeutic agent (palliative treatment of patients with cancer)	Immunex	MCCAC ¶¶ 104, 291; AMCC ¶¶ 98, 422, Appendix A; 2 AMCC ¶¶ 98, 422; 3 AMCC ¶¶ 118, 433; 4 AMCC ¶¶ 119, 405; 5th AMCC ¶¶ 119, 406	No	Yes	
				Sicor	AMCC ¶ 492; 2d AMCC ¶¶ 492, 502, 503; 3d AMCC ¶¶ 503, 513, 514, Appendix A; 4th AMCC ¶¶ 472, 482, 483, Appendix A; 5th AMCC ¶¶ 52, 473, 483, 484	No	Yes	
Leukine	B	Brand (not sold by Immunex after 7/02)	A biologic and white blood cell stimulant (including use for post-bone marrow transplant, post-chemotherapy with acute myeleogenous leukemia, and pre- and post-blood stem cell transplant)	Immunex	MCCAC ¶ 104; AMCC ¶¶ 98, 422; 2nd AMCC ¶¶ 98, 422; 3rd AMCC ¶¶ 118, 433; 4th AMCC ¶¶ 119, 405; 5th AMCC ¶¶ 119, 406	No	Yes	
Levofloxacin	B	Generic	Primarily used in the hospital setting as an antibiotic	Abbott	3rd AMCC ¶¶ 19, 20; 4th AMCC ¶ 21	Yes	Yes	
Lidocaine hydrochloride	B	Generic	Primarily used in the hospital setting as a local anesthetic	Abbott	3rd AMCC ¶¶ 15, 16, 20, 230; 4th AMCC ¶¶ 15, 17, 21, 227	Yes	Yes	
Liposyn II / Fat emulsion	B	Multi-Source	Primarily used in the hospital setting in order to provide calories to those receiving parenteral nutrition	Abbott	AMCC ¶ 201; 2nd AMCC ¶ 201, Appendix B; 3rd AMCC ¶ 217, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶ 214	No	Yes	
Lorazepam	B	Generic	Primarily used in the hospital setting to treat anxiety disorders	Abbott	AMCC ¶ 201; 2nd AMCC ¶ 201, Appendix A, Appendix B; 3rd AMCC ¶¶ 19, 39, 40, 217, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 21, 47, 48, 214	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
				Watson	AMCC ¶ 526; 2nd AMCC ¶¶ 526, Appendix A; 3rd AMCC ¶¶ 537, Appendix A and B; 4th AMCC ¶¶ 487, Appendix A	No	Yes	
Lovenox	B	Brand	An anticoagulant therapy used to prevent deep vein thrombosis following hip replacement, knee replacement, or stomach surgery	Aventis	3rd AMCC ¶15; 4th AMCC ¶15; 5th AMCC ¶15	Yes	Yes	
Lyphocin	B	Branded Multi-Source	Injectable antibiotic used primarily in hospital setting	Fujisawa	AMCC ¶ 364, Appendix A; 2nd AMCC ¶371, Appendix A; 3rd AMCC ¶380, Appendix A; 4th AMCC ¶381, Appendix A; 5th AMCC ¶353	No	Yes	
Magnese chloride	B	Generic	Primarily used in the hospital setting as an additive to IV solutions for total parenteral nutrition	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Magnesium sulfate	B	Generic	Primarily used in the hospital setting as an electrolyte replenisher	Abbott	3rd AMCC ¶ 15; 4th AMCC ¶ 15	Yes	Yes	
				Sicor	4th AMCC ¶ 15; 5th AMCC ¶ 15	Yes	Yes	
Mannitol	B	Generic	Primarily used in the hospital setting as a diuretic	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Marcaine	B	Generic	Primarily used in the hospital setting as a local anesthetic	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Medrol / Methylprednisolone	B	Multi-source	Anti-inflammatory	Pharmacia	2nd AMCC ¶ 115; 3rd AMCC ¶¶ 20, 132; 4th AMCC ¶ 133; 5th AMCC ¶ 133	No	Yes	
Metaproterenol sulfate	B	Generic	Indicated as a bronchodilator for bronchial asthma and for reversible bronchospasm wich may occur in association with bronchitis	Dey	MCCAC ¶¶ 90, 251, AMCC ¶¶ 81, 83, 349, 359, 360, Appendix A; 2nd AMCC ¶¶ 81, 83, 349, 359, 360, Appendix A; 3rd AMCC ¶¶ 104, 106, 365, 375, 376, Appendix A; 4th AMCC ¶¶ 105, 107, 337, 347, 348, Appendix A; Revised 5th AMCC, ¶¶ 105, 107, 337, 347, 348	No	Yes	
Methotrexate sodium	B	Multisource (not sold by Immunex after 6/01)	Anticancer agent	Immunex	MCCAC ¶ 291; AMCC ¶ 422, Appendix A; 2nd AMCC ¶ 422; 3rd AMCC ¶ 433; 4th AMCC ¶ 405; 5th AMCC ¶ 406	No	Yes	
Metoclopramide	B	Generic	Primarily used in the hospital setting as an antiemetic	Abbott	3rd AMCC ¶ 230 ; 4th AMCC ¶ 227	No	Yes	
Midazolam hydrochloride	B	Generic	Primarily used in the hospital setting as a sedative	Abbott	3rd AMCC ¶¶ 15, 16, 19; 4th AMCC ¶¶ 15, 17, 21	Yes	Yes	
Mithracin	B	Multi-Source	Antineoplastic cancer medication	Bayer	Modified 1st Am. Compl. ¶ 286; 2nd AMCC ¶ 286; 3rd AMCC ¶ 302, Appendix; 4th AMCC ¶¶ 6, 299, Appendix A; Appendix to 4th AMCC	No	Yes	
Monoclalte / Monoclalte-P	B	Multi-Source Biologic	Anti-hemophilic factor VIII:C, used to treat hemophilia	Aventis	MCCA ¶67; 1st AMCC ¶55; 2nd AMCC ¶55; 3rd AMCC ¶78; 4th AMCC ¶86; 5th AMCC ¶86	No	Yes	
Mononine	B	Multi-Source Biologic	Coagulation factor IX, used to treat hemophilia B	Aventis	MCCA ¶67; 1st AMCC ¶55; 2nd AMCC ¶55; 3rd AMCC ¶78; 4th AMCC ¶86; 5th AMCC ¶86	No	Yes	
Morphine sulfate	B	Generic	Primarily used in the hospital setting as a pain reliever	Abbott	3rd AMCC ¶¶ 15, 16; 4th AMCC ¶¶ 15, 17	Yes	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
Nadolol	B	Generic	Antihypertensive used in treatment of hypertension and angina	Watson	AMCC ¶¶ 526, 536; 2nd AMCC ¶¶ 526, 536, Appendixes A and B; 3rd AMCC ¶¶ 537, 547, Appendixes A and B; 4th AMCC ¶¶ 487, 495, 5th AMCC ¶ 488	No	Yes	
Naibuphine	B	Generic	Primarily used in the hospital setting as a pain reliever	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Nebupent	B	Branded Multi-Source	Oral anti-infective used in hospital setting to prevent and treat pneumo	Fujisawa	AMCC ¶ 364, Appendix A; 2nd AMCC ¶¶371, Appendix A; 3rd AMCC ¶380, Appendix A; 4th AMCC ¶381, Appendix A; 5th AMCC ¶353	No	Yes	
Neosar / Cyclophosphamide	B	Generic	Oncolitic	Pharmacia	CAC ¶ 41; 2nd AMCC ¶¶ 115, 458, 465, 466, 472, Ex. A, Ex. B; 3rd AMCC ¶¶ 132, 469, 476, 477, 483, Ex. A, Ex. B; 4th AMCC ¶¶ 133, 438, 445, 446, 452, App. A, App. B; 5th AMCC ¶¶ 133, 439, 446, 447, 453	No	Yes	
Neostigmine methylsulfate	B	Generic	Primarily used in the hospital setting to correct muscle strength	Abbott	3rd AMCC ¶¶ 15, 230; 4th AMCC ¶¶ 15, 227	No	Yes	
				Sicor	4th AMCC ¶ 15; 5th AMCC ¶ 15	Yes	Yes	
Novacaine / Procaine	B	Generic	Primarily used in the hospital setting as an anesthetic	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Novantrone	B	Brand (not sold by Immunex after 11/02)	Anticancer agent (including use for acute myeleogenous leukemia, hormone refractory prostate cancer, and relapsing-remitting multiple sclerosis)	Immunex	CAC ¶ 38; MCCAC ¶¶ 104, 291; MCCAC ¶¶ 104, 291; AMCC ¶¶ 98, 422, Appendix A; 2nd AMCC ¶¶ 98, 422; 3rd AMCC ¶¶ 118, 433; 4th AMCC ¶¶ 119, 405; 5th AMCC ¶¶ 119, 406	No	Yes	
Osmitrol	B	Multi-source	Primarily used in the hospital setting as a diuretic	Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A; 3rd AMCC ¶ 288, App A; 4th AMCC ¶ 285; 4th AMCC Revised App A; 5th AMCC ¶ 285	No	Yes	
Pancuronium bromide	B	Generic	Primarily used in the hospital setting as a muscle relaxer	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Pentam /Pentamidine isethionate	B	Branded Multi-Source	Anti-infective used primarily in hospital setting to treat AIDS related pneumonia	Fujisawa	CAC ¶31; MCCAC ¶93; AMCC ¶¶86, 364, 371, Appendix A; 2nd AMCC ¶ ¶86, 364, 371, Appendix A; 3rd AMCC ¶ ¶109, 380, 387, Appendix A; 4th AMCC ¶ ¶110, 381, 388, Appendix A; 5th AMCC ¶ ¶110, 353, 360-63	No	No	
		Generic		Sicor	AMCC ¶ 492; 2d AMCC ¶¶ 492, 503; 3d AMCC ¶¶ 503, 514, Appendix A; 4th AMCC ¶¶ 472, 483, Appendix A; 5th AMCC ¶¶ 473, 484	No	Yes	
Perphenazine	B	Generic	Psychotherapeutic agent used to manage psychotic disorders	Watson	AMCC ¶¶ 526, 536; 2nd AMCC ¶¶ 526, 536, Appendixes A and B; 3rd AMCC ¶¶ 537, 547, Appendixes A and B; 4th AMCC ¶¶ 487, 495, 5th AMCC ¶ 488	No	Yes	
Phenylephrine	B	Generic	Adrenergic receptor used primarily as a decongestant	Sicor	4th AMCC ¶ 15; 5th AMCC ¶ 15	Yes	Yes	
Potassium acetate / Potassium chloride	B	Generic	Primarily used in the hospital setting tp treat low blood levels	Abbott	3rd AMCC ¶¶ 15, 16, 230; 4th AMCC ¶¶ 15, 17, 227	Yes	Yes	
Prograf	B	Brand	Self-administered immunosuppressant used for transplants, Medicare Part B special	Fujisawa	CAC ¶ 31; AMCC ¶364, Appendix A; 2nd AMCC ¶371, Appendix A; 3rd AMCC ¶380, Appendix A; 4th AMCC ¶381, Appendix A; 5th AMCC ¶ ¶ 353, 360-63	No	Yes	
Promethazine	B	Generic	Primarily used in the hospital setting as an antihistamine	Abbott	3rd AMCC ¶¶ 15, 19, 20; 4th AMCC ¶¶ 15, 21	Yes	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
				Sicor	4th AMCC ¶¶ 15, 21; 5th AMCC ¶¶ 15, 21	Yes	Yes	
				Watson	4th AMCC ¶ 15	Yes	Yes	
Propranolol HCL	B	Generic	Beta blocker for treatment of hypertension and other cardiovascular conditions	Watson	AMCC ¶ 526; 2nd AMCC ¶ 526, Appendixes A and B; 3rd AMCC ¶ 537, Appendixes A and B; 4th AMCC ¶ 487, 5th AMCC ¶ 488	No	Yes	
Propofol	B	Generic	Primarily used in the hospital setting as an anesthetic	Abbott	3rd AMCC ¶ 15; 4th AMCC ¶ 15	Yes	Yes	
				Sicor	4th AMCC ¶ 15; 5th AMCC ¶ 15	Yes	Yes	
Ranitidine HCL	B	Generic	Antihistamine	Watson	AMCC ¶ 526; 2nd AMCC ¶ 526, Appendixes A and B; 3rd AMCC ¶ 537, Appendixes A and B; 4th AMCC ¶ 487	No	Yes	
Recombinate	B	Multi-Source Biologic	Anti-hemophilic factor (recombinant), used to treat hemophilia	Baxter	MCCAC ¶ 71; AMCC ¶¶ 60, 272; 2nd AMCC ¶¶ 60, 272, App A; 3rd AMCC ¶¶ 83, 288, App A; 4th AMCC ¶¶ 91, 285; 4th AMCC Revised App A; 5th AMCC ¶¶ 91, 285	No	Yes	
Sodium acetate	B	Generic	Primarily used in the hospital setting as a corticosteroid	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Sodium chloride	B	Generic	Primarily used in the hospital setting as a diluent, as a way to give injectable medicines to flush intravenous lines and for other conditions	Abbott	MCCAC ¶¶ 26, 54, 190; AMCC ¶¶ 29, 40, 187, 201; 2nd AMCC ¶¶ 29, 40, 187, 201, 208, Appendix A, Appendix B; 3rd AMCC ¶¶ 15, 16, 20, 21, 39, 63, 203, 217, 224, Amended List of Purchases Made By Plaintiffs; 4th AMCC ¶¶ 15, 17, 25, 47, 71, 200, 214, 221	No	Yes	
				Baxter	MCCAC ¶ 217, AMCC ¶¶ 60, 272; 2nd AMCC ¶¶ 60, 272, App A, App B; 3rd AMCC ¶¶ 83, 288, App A, App B; 4th AMCC ¶¶ 91, 285; 4th AMCC Revised App A, App B; 5th AMCC ¶¶ 91, 285	No	Yes	
				Dey	AMCC ¶ 360; 2nd AMCC ¶ 360; 3rd AMCC ¶ 376; 4th AMCC ¶ 348; Revised 5th AMCC ¶ 348	No	Yes	
				Sicor	4th AMCC ¶¶ 15, 17, 50; 5th AMCC ¶¶ 15, 17	Yes	Yes	
Solu-cortef / Hydrocortisone sodium succinate	B	Multi-source	Hormone	Pharmacia	2nd AMCC ¶¶ 115, 458, 466, Ex. A, Ex. B; 3rd AMCC ¶¶ 19, 132, 469, 477, Ex. A, Ex. B; 4th AMCC ¶¶ 133, 438, 446, App. A, App. B; 5th AMCC ¶¶ 133, 439, 447	No	Yes	
Solu-medrol	B	Multi-source	Anti-inflammatory	Pharmacia	2nd AMCC ¶¶ 458, 466, Ex. A, Ex. B; 3rd AMCC ¶¶ 21, 469, 477, Ex. A, Ex. B; 4th AMCC ¶¶ 133, 438, 446, App. A, App. B; 5th AMCC ¶¶ 133, 439, 447	No	Yes	
Succinylcholine chloride	B	Generic	Primarily used in the hospital setting as a muscle relaxer	Abbott	3rd AMCC ¶ 15; 4th AMCC ¶ 15	Yes	Yes	
Taxotere	B	Brand	A taxane used to treat a variety of cancers	Aventis	MCCA ¶67; 1st AMCC ¶250, and Appendix A; 2nd AMCC ¶250; 3rd AMCC ¶266; 4th AMCC ¶263; 5th AMCC ¶263	No	Yes	
Thioplex / Thiotepa	B	Brand (until 2001); multisource (2001-forward)	Chemotherapeutic agent (palliative treatment of patients with cancer)	Immunex	MCCAC ¶ 104; AMCC ¶¶ 98, 422; 2nd AMCC ¶¶ 98, 422; 3rd AMCC ¶¶ 118, 433; 4th AMCC ¶¶ 119, 405; 5th AMCC ¶¶ 119, 406	No	Yes	
Tobramycin sulfate / Tobramycin/sodium chloride	B	Generic	Primarily used in the hospital setting as an antibiotic for the treatment of lung infections	Sicor	MCCAC ¶ 323; AMCC ¶¶ 124, 492, 501; 2d AMCC ¶¶ 124, 492, 501, 502; 3d AMCC ¶¶ 141, 503, 512, Appendix A; 4th AMCC ¶¶ 142, 472, 481, Appendix A; 5th AMCC ¶¶ 142, 473, 482	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
				Abbott	MCCAC ¶¶ 54, 190; AMCC ¶¶ 40, 201, 208; 2 nd AMCC ¶¶ 40, 201, 208, Appendix A, Amended List of Purchases Made by Plaintiff; 3 rd AMCC ¶ 217, 224, Amended List of Purchases Made by Plaintiffs; 4 th AMCC ¶ 71, 214, 221	No	Yes	
Toposar [See Etoposide]	B	Generic	Primarily used in the hospital setting as a treatment for testicular cancer	Abbott	3rd AMCC ¶ 231; 4th AMCC ¶ 228	No	Yes	
				Pharmacia	CAC ¶ 41; 2nd AMCC ¶¶ 115, 187, 458, 465, 466, 469, 472, Ex. A, Ex. B; 3rd AMCC ¶¶ 52, 132, 203, 469, 476, 477, 480, 483, Ex. A, Ex. B; 4th AMCC ¶¶ 17, 60, 133, 438, 444, 445, 446, 449, 452, App. A, App. B; 5th AMCC ¶¶ 17, 60, 133, 200, 439, 446, 447, 450, 453	No	Yes	
				Sicor	MCCAC ¶ 319; AMCC ¶¶ 492, 496; 2d AMCC ¶¶ 492, 494, 496, 502, 503; 3d AMCC ¶¶ 503, 505, 507, 513, 514, Appendix A; 4th AMCC ¶¶ 17, 60, 472, 474, 476, 482, 483, Appendix A; 5th AMCC ¶¶ 17, 60, 473, 475, 477, 483, 484	No	Yes	
Travasol / Travasol with dextrose	B	Multi-source	Primarily used in the hospital setting as an additive to IV solutions for amino acid delivery	Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A; 3rd AMCC ¶ 288, App A; 4th AMCC ¶ 285; 4th AMCC Revised App A; 5th AMCC ¶ 285	No	Yes	
Trelstar / Triptorelin pamoate	B	Brand	Oncolytic	Pharmacia	3rd AMCC ¶ 53; 4th AMCC ¶ 61, App. A; 5th AMCC ¶ 61	Yes	Yes	
				Watson	4th AMCC Appendix A	Yes	Yes	
Vancocin / Vancocin HCL / Vancomycin/ Vancomycin HCL	B	Generic	Primarily used in the hospital setting as an antibiotic	Abbott	MCCAC ¶¶ 54, 185, 186, 187, 188, 190; AMCC @ TOC, ¶¶ 40, 201, 208, 209, 210, 211; 2nd AMCC @ TOC, ¶¶ 40, 201, 208, 209, 210, 211, Appendix A, Appendix B; 3rd AMCC ¶¶ 52, 63, 224, 225, 226, 227, Amended List of Purchases Made By Plaintiffs; 4th AMCC @ TOC, ¶¶ 21, 60, 71, 214, 221, 222, 223, 224	No	Yes	
				Baxter	AMCC ¶ 272; 2nd AMCC ¶ 272, App A, App B; 3rd AMCC ¶ 288, App A, App B; 4th AMCC ¶ 285; 4th AMCC Revised App A, App B; 5th AMCC ¶ 285	No	Yes	
				Fujisawa	MCCAC ¶93; AMCC ¶¶86, 364, 371, Appendix A; 2nd AMCC ¶ ¶86, 364, 371, Appendix A; 3rd AMCC ¶ ¶109, 380, 387, Appendix A; 4th AMCC ¶ ¶110, 381, 388, Appendix A; 5th AMCC ¶ ¶110, 353, 360-63	No	Yes	
				Watson	MCCAC ¶¶ 130, 327; AMCC ¶¶ 130, 187, 526, 534; 2nd AMCC ¶¶ 130, 187, 526, 534, Appendixes A and B; 3rd AMCC ¶¶ 147, 537, 545, Appendixes A and B; 4 AMCC ¶¶ 60, 140, 200, 487, 495, Appendix A	No	Yes	
Verapamil HCL	B	Generic	Cardiovascular agent used in treatment for angina and arrythmia	Watson	AMCC ¶ 526; 2nd AMCC ¶ 526, Appendixes A and B; 3rd AMCC ¶ 537, Appendixes A and B; 4th AMCC ¶¶ 487, 491, 5th AMCC ¶ 488	No	Yes	
Vinblastine sulfate	B	Generic	Chemotherapy drug used in clinical setting to treat certain cancers	Fujisawa	AMCC ¶ 364, Appendix A; 2nd AMCC ¶371, Appendix A; 3rd AMCC ¶380, Appendix A; 4th AMCC ¶381, Appendix A; 5th AMCC ¶ ¶110, 353, 360-63	No	Yes	
Vincasar / Vincristine / Vinscristine sulfate	B	Generic	Primarily used in the hospital setting as an oncolytic	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
		Multi-source		Pharmacia	1st Amd Compl ¶¶ 180, 182; 2nd AMCC ¶¶ 115, 458, 465, 466, 470, 471, Ex. A, Ex. B; 3rd AMCC ¶¶ 132, 469, 476, 477, 481, 482, Ex. A, Ex. B; 4th AMCC ¶¶ 21, 133, 438, 445, 446, 450, 451, 452, App. A, App. B; 5th AMCC ¶¶ 133, 439, 447, 451, 452, 453	No	Yes	

DRUG NAME	GROUP	TYPE	DESCRIPTION	NAMED DEFENDANT	COMPLAINT CITES	SUBJECT TO MOTION TO STRIKE	SUBJECT TO DISCOVERY	
		Generic		Sicor	4th AMCC ¶ 21; 5th AMCC ¶ 21	Yes	Yes	
Water for injection bacteriostatic	B	Generic	Primarily used in the hospital setting as a diluent	Abbott	3rd AMCC ¶ 230; 4th AMCC ¶ 227	No	Yes	
Zemplar	B	Branded	Primarily used in the hospital setting as a man-made form of vitamin D	Abbott	MCCAC ¶ 54; AMCC ¶ 40; 2nd AMCC ¶ 40; 3rd AMCC ¶ 63; 4th AMCC ¶ 71	No	Yes	
Zinc chloride	B	Generic	Primarily used in the hospital setting as an antiseptic	Abbott	3rd AMCC ¶ 227; 4th AMCC ¶ 227	No	Yes	